The simultaneous use of HSP90 inhibitors in combination with drugs having different mechanisms of action can simultaneously target various clones within a cancer cell population and delay or suppress the development of adaptive drug resistance, which typically emerges over time with single-drug treatments. This evidence concerns the gene HSP90AB1 and cancer.